Optomed Q4: US and Europe new strategic markets - Redeye

Redeye maintains its positive view and valuation of Optomed. The company refocuses its sales efforts from the Eastern markets to the USA and Western Europe. Stability, advanced healthcare system (especially in digital health), as well as implemented reimbursements, are a better match for the company's sophisticated eye screening solutions. This change will also increase the predictability of revenues.

Länk till analysen i sin helhet: https://www.redeye.se/research/833542/optomed-q4-us-and-europe-new-revenue-focus?utm_source=finwire&utm_medium=RSS